Collegium Pharmaceutical, Inc. (COLL)
- Previous Close
35.84 - Open
35.95 - Bid 36.35 x 200
- Ask 36.46 x 200
- Day's Range
35.79 - 36.57 - 52 Week Range
20.83 - 40.95 - Volume
121,316 - Avg. Volume
410,536 - Market Cap (intraday)
1.191B - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
28.23 - EPS (TTM)
1.29 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
40.00
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
www.collegiumpharma.com197
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: COLL
Performance Overview: COLL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COLL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COLL
Valuation Measures
Market Cap
1.19B
Enterprise Value
1.55B
Trailing P/E
28.23
Forward P/E
5.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.69
Price/Book (mrq)
6.09
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
5.04
Financial Highlights
Profitability and Income Statement
Profit Margin
8.50%
Return on Assets (ttm)
10.28%
Return on Equity (ttm)
24.68%
Revenue (ttm)
566.77M
Net Income Avi to Common (ttm)
48.16M
Diluted EPS (ttm)
1.29
Balance Sheet and Cash Flow
Total Cash (mrq)
310.55M
Total Debt/Equity (mrq)
345.02%
Levered Free Cash Flow (ttm)
274.32M
Research Analysis: COLL
Company Insights: COLL
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: COLL
COLL: Rating increased to a BUY
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of BUY; a target price of $38.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetCOLL: Lowering target price to $37.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetCOLL: Raising target price to $41.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCOLL: Lowering target price to $40.00
COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $40.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target